Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pralatrexate + CHOP in PTCL
NCT02594267Phase 1Completed
- Sponsor
- Acrotech Biopharma Inc
- Start
- Nov 2015
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pralatrexate in peripheral T-cell lymphoma (PTCL), sponsored by Acrotech Biopharma Inc. Primary endpoint: Maximum Tolerated Dose at 126 Days. Started Nov 2015; status: completed.
02
Drugs
pralatrexate
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT02594267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02594267.